Upside Foods Claims Million-Pound Cultivated Chicken Capacity and a California Restaurant Launch

Upside Foods says it can now produce more than one million pounds of edible cultivated chicken a year without slaughtering animals. Chief executive Uma Valeti says the company can match the price range of really high-quality organic chicken. TechCrunch
The company also said its product will now be available at several restaurants in California. Upside says it has secured its next set of regulatory approvals from the U.S. Food and Drug Administration and the U.S. Department of Agriculture.
To make the case on taste, the company pointed to a video shot at its facilities. Jimmy Donaldson, the YouTuber known as MrBeast, visited Upside Foods and taste-tested a conventional chicken sandwich against one made with Upside's cultivated chicken, on camera. He could not identify which was which.
Upside Foods describes the process in more detail. According to the site, production starts with cell samples taken from a single egg of a heritage-breed chicken. The company says the cell sample can be stored and used for years. It also says all the chicken it has ever manufactured came from that one egg, so the lineage is presented as a point of provenance rather than a product detail.
From storage, selected cells go into a cultivator tank, which Upside likens to a brewery tank. The cells are fed a nutrient blend of water, sugars, amino acids, vitamins and minerals. The company describes the result as real chicken made without killing animals.
The one-million-pound figure is a stated capacity, not a record of sales. The price parity claim is a comparison Valeti makes against organic product, not a published price list. The approvals and the California restaurant rollout are announcements, so their practical reach will show up over time in menus, distribution and any further agency action.
In my view, the more useful way to read these claims is as a test of scale. Culture-based protein, meaning meat grown from animal cells in tanks rather than raised on a farm, has long been constrained by the cost and consistency of its growth medium and by how much bioreactor capacity exists. Upside's figures speak to both. If the price and volume claims hold at restaurant and retail volumes, the question shifts from whether the product can be made to how efficiently a banked cell line can be grown, fed and harvested at industrial scale. That is an engineering and supply-chain problem, and the sector's cost curve will ultimately answer it.
For now, the verifiable facts are a stated capacity of over one million pounds a year, a California restaurant launch, a claimed next set of FDA and USDA approvals, and a production method built on a single banked egg-derived cell line. Each is an assertion the market will test in the coming months.


